Zobrazeno 1 - 10
of 91
pro vyhledávání: '"Alain Depierre"'
Autor:
V. Westeel, J.-C. Dalphin
Publikováno v:
Revue des Maladies Respiratoires. 31:197
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Westeel, V., Dalphin, J.-C.
Publikováno v:
Revue des Maladies Respiratoires; March 2014, Vol. 31 Issue: 3 p197-197, 1p
Autor:
Denis Moro-Sibilot, Christophe Hennequin, Pierre Mouillefarine, Marc Riquet, Cécile Le Péchoux, Jean-Yves Douillard, Gérard Zalcman, Fabien Vaylet, Annie Giniès, Elisabeth Quoix, Alain Depierre, Bernard Milleron, Benjamin Besse, Jean-François Regnard, Sylvie Guillo, Clotilde Séblain-El Guerche
Publikováno v:
Oncologie. 9:800-809
Introduction La mise a jour des recommandations pour la pratique clinique (RPC) pour le traitement perioperatoire des patients atteints d’un cancer bronchique non a petites cellules resecable d’emblee, operables a ete elaboree par la Federation n
Autor:
Didier Debieuvre, S. Hominal, Radj Gervais, Jean-Louis Pujol, Olivier Molinier, Jean-Luc Breton, Dominique Tonelli, Elisabeth Quoix, Fouad Namouni, Alain Depierre, Bernard Milleron
Publikováno v:
Journal of Thoracic Oncology. 1(4):328-334
Introduction We designed this phase II trial to evaluate the efficacy and safety of weekly paclitaxel in combination with monthly carboplatin as first-line treatment in elderly patients with advanced non-small cell lung cancer (NSCLC). Methods Main e
Autor:
Denis Moro-Sibilot, Denis Braun, Virginie Westeel, Bernard Lebeau, Elisabeth Quoix, Alain Depierre, Bernard Milleron
Publikováno v:
Chest. 128:1442-1447
Background Pathologic complete response (CR) to preoperative chemotherapy has been shown to be a strong prognostic factor in resected non-small cell lung cancer (NSCLC). This preoperative setting offers the opportunity to evaluate the clinical predic
Autor:
Jean-Yves Douillard, Andrea Bezjak, Dongsheng Tu, Katherine Hann, Armando Santoro, Daniel Betticher, Luis Paz-Ares, Frances A. Shepherd, Christian Peschel, Maurizio Voi, Jeffrey S. Humphrey, Andrew Arnold, Jeffrey Crawford, Natasha B. Leighl, Lesley Seymour, Jacek Jassem, Susan M. Galbraith, Alain Depierre, Ulrich Gatzemeier
Publikováno v:
Journal of Clinical Oncology. 23:2831-2839
Purpose To determine whether BMS-275291, a broad-spectrum matrix metalloproteinase inhibitor (MMPI), added to systemic chemotherapy improved survival in advanced non–small-cell lung cancer (NSCLC). In early phase studies, BMS- 275291 was not associ
Autor:
R. Kessler, J.-L. Breton, D. Debieuvre, Xavier Quantin, Denis Moro-Sibilot, B. Milleron, D. Spaeth, P. Rebattu, Alain Depierre, J.L. Pujol, C. Clary, Radj Gervais, D. Braun, D. Castera, P.J. Souquet, H. Janicot, Etienne Lemarié, Jean-François Morère
Publikováno v:
Annals of Oncology. 16:602-610
Background This multicenter, randomized, phase III study compared the efficacy, including progression-free survival (PFS), and safety of gemcitabine–docetaxel (GD) combination versus cisplatin–vinorelbine (CV) in the treatment of advanced non-sma
Autor:
Didier Debieuvre, J.-L. Breton, Bernard Lebeau, P. Clouet, Bernard Milleron, Fabien Vaylet, Gérard Zalcman, Alain Depierre, J. M. Brechot, D. Moro-Sibilot, A. Vergnenegre, Etienne Lemarié, E. Quoix, J.L. Pujol, A. Ducolone
Publikováno v:
Annals of Oncology. 15:38-44
Background The survival benefit associated with first-line chemotherapy in advanced lung cancer led to the need for second-line chemotherapy. Docetaxel (Taxotere®) has proven efficacy in both settings. This study evaluated the safety and efficacy of
Autor:
Alain Depierre, Virginie Westeel
Publikováno v:
American Journal of Respiratory Medicine. 2:477-490
Among all nonmetastatic non-small-cell lung cancer (NSCLC) patients, the best survival rates are observed in patients who undergo surgery. Nevertheless, 5-year survival rates vary between 20% and 60% depending on the stage of the disease. Several com